

Brazil

Population 2018

209 million

Estimates of TB burden ^o , 2018	Number (thousands)	Rate (per 100 000 population)
Total TB incidence	95 (81–110)	45 (39–52)
HIV-positive TB incidence	11 (9.3–13)	5.2 (4.4–6)
MDR/RR-TB incidence ^{oo}	2.5 (1.9–3.2)	1.2 (0.89–1.5)
HIV-negative TB mortality	4.8 (4.6–5)	2.3 (2.2–2.4)
HIV-positive TB mortality	1.9 (1.4–2.4)	0.88 (0.66–1.1)

Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases	1.5% (1.1–2)
Previously treated cases	8% (6–10)

TB case notifications, 2018

Total new and relapse	82 409
- % tested with rapid diagnostics at time of diagnosis	34%
- % with known HIV status	79%
- % pulmonary	87%
- % bacteriologically confirmed ^{ooo}	74%
- % children aged 0-14 years	3%
- % women	29%
- % men	68%
Total cases notified	90 527

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2018	7% (6–8)

TB/HIV care in new and relapse TB patients, 2018

	Number	(%)
Patients with known HIV status who are HIV-positive	7 445	11%
- on antiretroviral therapy	3 776	51%

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance ^{ooo}	
- New cases	43%
- Previously treated cases	48%
Laboratory-confirmed cases*	MDR/RR-TB: 1 119, XDR-TB: 26
Patients started on treatment**	MDR/RR-TB: 746, XDR-TB: 26
MDR/RR-TB cases tested for resistance to second-line drugs	141

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2017	71%	78 652
Previously treated cases, excluding relapse, registered in 2017	39%	7 350
HIV-positive TB cases registered in 2017	51%	7 617
MDR/RR-TB cases started on second-line treatment in 2016	61%	546
XDR-TB cases started on second-line treatment in 2016	41%	17

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2019

National TB budget (US\$ millions)	38
Funding source: 100% domestic, <1% international, 0% unfunded	

^o Ranges represent uncertainty intervals

^{oo} MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin


^{ooo} Calculated for pulmonary cases only

* Includes cases with unknown previous TB treatment history

** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




— Total TB incidence
— New and relapse TB cases notified
— HIV-positive TB incidence

(Rate per 100 000 population per year)




— HIV-negative TB mortality

Notified cases by age group and sex, 2018




■ Females ■ Males □ Incidence

Treatment success rate (%)



— New and relapse
— Retreatment, excluding relapse
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)



■ Unfunded
■ Funded internationally
■ Funded domestically